SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced that members of the management team will present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 3:00 pm PT in Las Vegas.
To access the live webcast of the Alector presentation, please visit the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcast will be available on the Alector website for 30 days following the conference.
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Source: Alector, Inc.
Dan Budwick, 973-271-6085